Non-activated APJ suppresses the angiotensin II type 1 receptor, whereas apelin-activated APJ acts conversely

Hypertension Research

Volumn 34, Issue 6, 2011, Pages 701-706

  Sun, Xiao ^a   Iida, Shinichiro ^b   Yoshikawa, Ayumu ^c   Senbonmatsu, Rina ^d   Imanaka, Kazuhito ^a   Maruyama, Kei ^c   Nishimura, Shigeyuki ^b   Inagami, Tadashi ^e   Senbonmatsu, Takaaki ^c  

^a SAITAMA MEDICAL CENTER   (Japan)

^b SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d BATES COLLEGE   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

angiotensin II type 1 receptor; angiotensin II type 1 receptor blocker; apelin; APJ

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 5 ACETYL 4,5,6,7 TETRAHYDRO 2 PROPYL 3 [2' (1H TETRAZOL 5 YL) 4 BIPHENYLYLMETHYL]IMIDAZO[4,5 C]PYRIDINE 4 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; APELIN; APELIN RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PERTUSSIS TOXIN;

ARTICLE; CARDIOVASCULAR SYSTEM; CELL STRAIN HEK293; DIMERIZATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HEART PROTECTION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

CELLS, CULTURED; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PERTUSSIS TOXIN; PHOSPHORYLATION; RECEPTOR CROSS-TALK; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 79958129079     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.19     Document Type: Article

References (36)

1. O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, Shi X, Petronis A, George SR, Nguyen T. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993; 136: 355-360. (Pubitemid 24049270)
2. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 251: 471-476. (Pubitemid 28505047)
3. Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y, Hinuma S, Kitada C, Honda S, Kurokawa T, Onda H, Nishimura O, Fujino M. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem 2000; 275: 21061-21067. (Pubitemid 30481796)
4. Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept 2005; 126: 233-240. (Pubitemid 40128188)
5. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005; 107: 198-211. (Pubitemid 40916219)
6. Lee DK, George SR, O'Dowd BF. Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends Pharmacol Sci 2006; 27: 190-194.
7. Kidoya H, Naito H, Takakura N. Apelin induces enlarged and non-leaky blood vessels for functional recovery from ischemia. Blood 2010; 115: 3166-3174.
8. Farkasfalvi K, Stagg MA, Coppen SR, Siedlecka U, Lee J, Soppa GK, Marczin N, Szokodi I, Yacoub MH, Terracciano CM. Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem Biophys Res Commun 2007; 357: 889-895. (Pubitemid 46711085)
9. Japp AG, Cruden NL, Barnes G, van Gemeren N, Mathews J, Adamson J, Johnston NR, Denvir MA, Megson IL, Flapan AD, Newestern bloty DE. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation 2010; 121: 1818-1827.
10. Iwanaga Y, Kihara Y, Takenaka H, Kita T. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: possible role of angiotensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol 2006; 41: 798-806. (Pubitemid 44635562)
11. Ishida J, Hashimoto T, Hashimoto Y, Nishiwaki S, Iguchi T, Harada S, Sugaya T, Matsuzaki H, Yamamoto R, Shiota N, Okunishi H, Kihara M, Umemura S, Sugiyama F, Yagami K, Kasuya Y, Mochizuki N, Fukamizu A. Regulatory roles for APJ a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 2004; 279: 26274-26279. (Pubitemid 38798776)
12. Chun HJ, Ali ZA, Kojima Y, Kundu RK, Sheikh AY, Agrawal R, Zheng L, Leeper NJ, Pearl NE, Patterson AJ, Anderson JP, Tsao PS, Lenardo MJ, Ashley EA, Quertermous T. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 2008; 118: 3343-3354.
13. Hashimoto T, Kihara M, Imai N, Yoshida S, Shimoyamada H, Yasuzaki H, Ishida J, Toya Y, Kiuchi Y, Hirawa N, Tamura K, Yazawa T, Kitamura H, Fukamizu A, Umemura S. Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol 2007; 171: 1705-1712. (Pubitemid 350158330)
14. Liu C, Su T, Li F, Li L, Qin X, Pan W, Feng F, Chen F, Liao D, Chen L. PI3K/Akt signaling transduction pathway is involved in rat vascular smooth muscle cell proliferation induced by apelin-13. Acta Biochim Biophys Sin 2010; 42: 396-402.
15. Yoshida T, Mishina M. Neuron-specific gene manipulations to transparent zebrafish embryos. Methods Cell Sci 2003; 25: 15-23. (Pubitemid 38100460)
16. Kawai M, Maruyama H, Bessho K, Yamamoto H, Miyazaki J, Yamamoto T. Simple strategy for bone regeneration with a BMP-2/7 gene expression cassette vector. Biochem Biophys Res Commun 2009; 390: 1012-1027.
17. Li Z, Zhang H, Lundin L, Thullberg M, Liu Y, Wang Y, Claesson-Welsh L, Stromblad S. p21-activated kinase 4 phosphorylation of integrin beta5 Ser-759 and Ser-762 regulates cell migration. J Biol Chem 2010; 285: 23699-23710.
18. Hashimoto Y, Harada Y, Narita H, Naito K, Murata S. The pharmacologic profile of 606A, a novel angiotensin II receptor antagonist. J Cardiovasc Pharmacol 1997; 29: 284-290. (Pubitemid 27097733)
19. Prinster SC, Hague C, Hall RA. Heterodimerization of g protein-coupled receptors: specificity and functional significance. Pharmacol Rev 2005; 57: 289-298. (Pubitemid 41196951)
20. Levoye A, Dam J, Ayoub MA, Guillaume JL, Couturier C, Delagrange P, Jockers R. The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J 2006; 25: 3012-3023. (Pubitemid 44106754)
21. Terrillon S, Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO Rep 2004; 5: 30-34. (Pubitemid 38228524)
22. Rios CD, Jordan BA, Gomes I, Devi LA. G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol Ther 2001; 92: 71-87. (Pubitemid 34251127)
23. Gines S, Hillion J, Torvinen M, Le Crom S, Casado V, Canela EI, Rondin S, Lew JY, Watson S, Zoli M, Agnati LF, Verniera P, Lluis C, Ferre S, Fuxe K, Franco R. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc Natl Acad Sci USA 2000; 97: 8606-8611. (Pubitemid 30639720)
24. Masri B, Lahlou H, Mazarguil H, Knibiehler B, Audigier Y. Apelin (65-77) activates extracellular signal-regulated kinases via a PTX-sensitive G protein. Biochem Biophys Res Commun 2002; 290: 539-545. (Pubitemid 34694535)
25. Masri B, Morin N, Pedebernade L, Knibiehler B, Audigier Y. The apelin receptor is coupled to Gi1 or Gi2 protein and is differentially desensitized by apelin fragments. J Biol Chem 2006; 281: 18317-18326. (Pubitemid 44035488)
26. Hamada J, Kimura J, Ishida J, Kohda T, Morishita S, Ichihara S, Fukamizu A. Evaluation of novel cyclic analogues of apelin. Int J Mol Med 2008; 22: 547-552.
27. AbdAlla S, Lother H, el Massiery A, Quitterer U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 2001; 7: 1003-1009. (Pubitemid 32937379)
28. Barki-Harrington L, Luttrell LM, Rockman HA. Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation 2003; 108: 1611-1618. (Pubitemid 37187789)
29. AbdAlla S, Lother H, Abdel-tawab AM, Quitterer U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem 2001; 276: 39721-39726.
30. Horiuchi M, Hayashida W, Akishita M, Tamura K, Daviet L, Lehtonen JY, Dzau VJ. Stimulation of different subtypes of angiotensin II receptors AT1 and AT2 receptors, regulates STAT activation by negative crosstalk. Circ Res 1999; 84: 876-882. (Pubitemid 29196731)
31. Miura S, Matsuo Y, Kiya Y, Karnik SS, Saku K. Molecular mechanisms of the antagonistic action between AT1 and AT2 receptors. Biochem Biophys Res Commun 2010; 391: 85-90.
32. Eberhardt RT, Kevak RM, Kang PM, Frishman WH. Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy. J Clin Pharmacol 1993; 33: 1023-1038. (Pubitemid 24002893)
33. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14 (Suppl 1): S73-S86.
34. Wassmann S, Czech T, van Eickels M, Fleming I, Böhm M, Nickenig G. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 2004; 110: 3062-3067. (Pubitemid 39491999)
35. Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P, Morigi M, Coffman TM, Remuzzi G. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 2009; 119: 524-530.
36. Cassis P, Conti S, Remuzzi G, Benigni A. Angiotensin receptors as determinants of life span. Pflugers Arch 2010; 459: 325-332.